Literature DB >> 19940138

c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins.

Jun Ni1, Alla Waldman, Levon M Khachigian.   

Abstract

Coronary artery bypass graft failure represents an unsolved problem in interventional cardiology and heart surgery. Late occlusion of autologous saphenous vein bypass grafts is a consequence of neointima formation underpinned by smooth muscle cell (SMC) migration and proliferation. Poor long term patency and the lack of pharmacologic agents that prevent graft failure necessitate effective alternative therapies. Our objective here was to evaluate the effect of targeted inhibition of the bZIP transcription factor c-Jun on intimal hyperplasia in human saphenous veins and vein graft stenosis after autologous end-to-side transplantation. DNAzymes targeting c-Jun attenuated intimal hyperplasia in human saphenous vein explants. Adenovirus-forced c-Jun expression stimulated SMC proliferation, proliferating cell nuclear antigen, and MMP-2 expression. c-Jun DNAzymes abrogated Adeno-c-Jun-inducible SMC growth and wound repair and reduced intimal thickening in jugular veins of New Zealand white rabbits 4 weeks after autologous end-to-side transplantation to carotid arteries. Conversely, in a DNAzyme-free setting, Adeno-c-Jun potentiated neointima formation in the veins compared with Adeno-LacZ. Inducible c-Jun expression is ERK1/2- and JNK-dependent but p38-independent. Injury- and shear-inducible c-Jun controls early growth response-1. These data demonstrate that strategies targeting c-Jun may be useful for the prevention of vein graft stenosis. Control of one important shear-responsive transcription factor by another indicates the existence of transcriptional amplification mechanisms that magnify the vascular response to cell injury or stress through inducible transcriptional networks.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19940138      PMCID: PMC2823545          DOI: 10.1074/jbc.M109.078345

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Perivenous support reduces early changes in human vein grafts: studies in whole blood perfused human vein segments.

Authors:  W Stooker; H W Niessen; A Baidoshvili; W R Wildevuur; V W Van Hinsbergh; J Fritz; C R Wildevuur; L Eijsman
Journal:  J Thorac Cardiovasc Surg       Date:  2001-02       Impact factor: 5.209

2.  Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.

Authors:  A Ehsan; M J Mann; G Dell'Acqua; V J Dzau
Journal:  J Thorac Cardiovasc Surg       Date:  2001-04       Impact factor: 5.209

3.  Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins.

Authors:  S J George; A H Baker; G D Angelini; A C Newby
Journal:  Gene Ther       Date:  1998-11       Impact factor: 5.250

4.  Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat.

Authors:  L Zezina; E Larsson; B Fellström
Journal:  Transpl Immunol       Date:  2001-02       Impact factor: 1.708

5.  Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3.

Authors:  S J George; C T Lloyd; G D Angelini; A C Newby; A H Baker
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

6.  New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury.

Authors:  F S Santiago; H C Lowe; M M Kavurma; C N Chesterman; A Baker; D G Atkins; L M Khachigian
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

Review 7.  AP-1 in cell proliferation and survival.

Authors:  E Shaulian; M Karin
Journal:  Oncogene       Date:  2001-04-30       Impact factor: 9.867

8.  Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis.

Authors:  H C Lowe; R G Fahmy; M M Kavurma; A Baker; C N Chesterman; L M Khachigian
Journal:  Circ Res       Date:  2001-10-12       Impact factor: 17.367

9.  Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein.

Authors:  J L Johnson; G J van Eys; G D Angelini; S J George
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-07       Impact factor: 8.311

10.  Comparison of the heparin coated vs the uncoated Jostent--no influence on restenosis or clinical outcome.

Authors:  J Wöhrle; E Al-Khayer; U Grötzinger; C Schindler; M Kochs; V Hombach; M Höher
Journal:  Eur Heart J       Date:  2001-10       Impact factor: 29.983

View more
  15 in total

1.  Fluid Mechanics, Arterial Disease, and Gene Expression.

Authors:  John M Tarbell; Zhong-Dong Shi; Jessilyn Dunn; Hanjoong Jo
Journal:  Annu Rev Fluid Mech       Date:  2014-01       Impact factor: 18.511

2.  Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).

Authors:  Yue Li; Ravinay Bhindi; Zhou J Deng; Stephen W Morton; Paula T Hammond; Levon M Khachigian
Journal:  Int J Cardiol       Date:  2013-07-22       Impact factor: 4.164

Review 3.  Early growth response-1 in the pathogenesis of cardiovascular disease.

Authors:  Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2016-06-01       Impact factor: 4.599

Review 4.  Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies.

Authors:  Akihito Muto; Lynn Model; Kenneth Ziegler; Sammy D D Eghbalieh; Alan Dardik
Journal:  Circ J       Date:  2010-07-01       Impact factor: 2.993

Review 5.  Activation transcription factor-4 and the acute vascular response to injury.

Authors:  Kristine P Malabanan; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-03-21       Impact factor: 4.599

Review 6.  Therapeutic strategies to combat neointimal hyperplasia in vascular grafts.

Authors:  Michael J Collins; Xin Li; Wei Lv; Chenzi Yang; Clinton D Protack; Akihito Muto; Caroline C Jadlowiec; Chang Shu; Alan Dardik
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-05

Review 7.  Fluid flow mechanotransduction in vascular smooth muscle cells and fibroblasts.

Authors:  Zhong-Dong Shi; John M Tarbell
Journal:  Ann Biomed Eng       Date:  2011-04-09       Impact factor: 3.934

Review 8.  Vein graft failure.

Authors:  Christopher D Owens; Warren J Gasper; Amreen S Rahman; Michael S Conte
Journal:  J Vasc Surg       Date:  2013-10-03       Impact factor: 4.268

9.  Shear stress modulation of smooth muscle cell marker genes in 2-D and 3-D depends on mechanotransduction by heparan sulfate proteoglycans and ERK1/2.

Authors:  Zhong-Dong Shi; Giya Abraham; John M Tarbell
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

10.  Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER).

Authors:  Eun-Ae Cho; Fergal J Moloney; Hong Cai; Annie Au-Yeung; Carlos China; Richard A Scolyer; Benafsha Yosufi; Mark J Raftery; Jason Z Deng; Stephen W Morton; Paula T Hammond; Hendrik-Tobias Arkenau; Diona L Damian; Douglas J Francis; Colin N Chesterman; Ross St C Barnetson; Gary M Halliday; Levon M Khachigian
Journal:  Lancet       Date:  2013-05-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.